Neumedicines

Neumedicines Phase 1b Study Shows HemaMax™ is Safe and Well-Tolerated at a Human Dose Equivalent to an Efficacious Dose in Non-human Primates

PASADENA, Calif. (December 18, 2012) – Neumedicines Inc., a privately held company developing therapies based on Interleukin-12 (IL-12) as a radiation medical countermeasure and for the treatment of chemotherapy-induced thrombocytopenia, announces that results from a Phase 1b study with 60 healthy volunteers showed HemaMax™ (rHuIL-12) to be safe and well-tolerated within a dose range that is predicted to be effective in humans as a treatment for hematopoietic syndrome of acute radiation syndrome (HSARS). The purpose of the Phase 1b study was to expand the human safety data to 60 healthy subjects at the highest safe dose following a first-in-human dose escalation study with 32 healthy subjects completed in March 2012.

HemaMax™ is being developed by Neumedicines under the U.S. Food and Drug Administration's (FDA) Animal Efficacy Rule to treat HSARS that could result from a nuclear or radiological weapon, or from a nuclear accident. This approval pathway requires demonstration of efficacy in representative animal models, as well as safety, pharmacokinetic and pharmacodynamic testing in healthy human volunteers.

"Our studies in both mice and rhesus monkeys demonstrate that a single, low-dose subcutaneous injection of HemaMax™ at 24 hours post-lethal radiation exposure has the remarkable ability to increase survival in the absence of supportive care, such as antibiotics, fluids and blood products," said Neumedicines President and Chief Executive Officer Lena Basile, J.D., Ph.D.

"The ability of just a single dose of HemaMax™ to increase survival will facilitate the speed and breadth in which this potentially life-saving therapeutic can be disseminated to victims in the event of a mass casualty radiation disaster, where HemaMax™ is positioned to be given to all potential victims without waiting for dosimetry results. This feature of HemaMax™ allows for this life-saving therapeutic to be administered without wasting precious time waiting for the results of a blood test or other analyses, as the effectiveness of all radiation countermeasures diminish rapidly with time of administration. Now we have further evidence that the dose level proven efficacious in animal models is safe and well-tolerated in humans. Data from this study will be an important component in a submission of a Biologic License Application (BLA) to FDA under the Animal Rule."

Preclinical and clinical studies have been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contracts No. HHSO1002000800060C and No. HHSO100201100037C.

About HemaMax™ (rHuIL-12)

HemaMax™ (NMIL12-1) is based on rHuIL-12 (recombinant human Interleukin–12). Scientists from Neumedicines discovered the previously unexplored hematological properties of IL-12 by

demonstrating the potent survival effects of single, low-dose IL-12 on hematopoietic recovery following lethal radiation. HemaMax™ is a new therapeutic that is predicted to be administered to humans in very low, nanogram per kilogram doses to achieve potent radiomitigation effects. To date, Neumedicines has demonstrated that HemaMax™ can increase survival in mice and non-human primates who receive the therapeutic in single, low doses 24 hours after lethal radiation exposure.

About Neumedicines Inc.
Neumedicines Inc. is developing protein therapeutics that address unmet clinical and societal needs in the fields of oncology, hematology and immunology. The company's lead product candidate is HemaMax™ (recombinant human interleukin-12, or rHuIL-12), which functions by targeting multiple pathways of hematopoiesis and innate immunity. HemaMax™ is being development as a biodefense radiation medical countermeasure and for indications in oncology, initially for chemotherapy-induced thrombocytopenia. Neumedicines is committed to developing and maximizing the scientific, clinical and commercial potential of its product pipeline. For more information, please visit www.neumedicines.com or follow the Company on Twitter @Neumedicines.

# # #